Fennec Pharmaceuticals Inc. Q2 FY2025 earnings call

• Stabilization and strategy: Jeff Hackman joined a year ago with a focus on stabilizing the business, sharpening strategy, and building a foundation for growth. They've achieved 3 consecutive quarters of growth.
• Awareness and adoption: Significant progress in increasing awareness of PEDMARK among oncology and broader cancer care communities through conferences, campaigns, and peer interactions. A large national oncology group added PEDMARK to its formulary for patients under 40.
• Clinical alignment: Held advisory boards with academic centers, NCODA issued a positive PQI for PEDMARK, providing guidance on its use. Engaged multidisciplinary healthcare professionals like ENTs, audiologists, etc.
• Access: Progress with payers and providers, strengthened Fennec HEARS patient assistance program with quarter-over-quarter enrollment growth.
• Patient/caregiver education: Supported advocacy associations and initiatives like Childhood Cancer Awareness month. Senior leadership to ring NASDAQ closing bell.

For the second quarter of 2025, Fennec Pharmaceuticals recorded net product sales of $9.7 million. This represents a 33% increase compared to the same period last year and a 10% sequential growth. It marks the third consecutive quarter of sequential growth in net product sales. The revenue contribution is primarily from PEDMARK, which is the first and only FDA-approved therapy for preventing cisplatin-induced ototoxicity.

• Anticipate most significant quarterly growth in H2 2025 as foundational pillars impact PEDMARK growth.
• Potential milestones and royalties from Norgine partnership, including EU rollout plans.
• Possible monetization or partnership after Japan study results expected in Q4.

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from forward-looking statements. Risks are detailed in press releases and SEC filings.

Q: Chase Knickerbocker asked about active prescribers number within AYA. Jeff Hackman responded that they don't share cumulative numbers but mentioned AYA market has 20,000 patients treated with cisplatin and growth from expanding current accounts.

Q: Sudan Loganathan asked about mix of new and repeat customers. Jeff Hackman said initially mostly new customers, now seeing more repeat customers but didn't give exact percentages.

Q: Chad asked about NCODA PQI and difference from NCCN guidelines. Jeff Hackman explained NCODA PQIs are peer-reviewed guidance for practice management, more focused than NCCN guidelines.

Q: Eduardo asked about EU timeline and Germany pricing. Robert Andrade said Norgine started in U.K. with traction, plans to roll out to EU5 and Nordic regions later, with milestones related to German pricing.